In oral tablet manufacture, liposomal minoxidil API is introduced as a lyophilized cake or spray-dried matrix with residual moisture below 2.0% w/w by Karl Fischer titration according to USP <921>. Low-dose compounded tablets containing 2.5 mg or 5.0 mg minoxidil as liposomal API are blended with microcrystalline cellulose PH-102, anhydrous lactose, crospovidone, and colloidal silicon dioxide. Geometric dilution is required because the API fraction can fall below 1.0% w/w of total core weight for low-dose units; a five-stage serial trituration with an API-to-lactose preblend at 1:10 is used before addition to the main blender. Blend uniformity is tested by sampling at 10 locations using a side-sampling thief, with acceptance set at RSD ≤ 5.0% before lubrication. Lubrication is limited to 0.5% w/w magnesium stearate for 3 minutes in a V-blender at 25 rpm; prolonged lubrication reduces dissolution rate. Direct compression on a Korsch XL 100 rotary press is performed at compaction force 6–12 kN, with tablet hardness controlled to 4–7 kp and friability ≤ 0.8% by USP <1216>. Disintegration is tested in purified water at 37°C with a requirement of ≤ 15 minutes per USP <701>. Dissolution is assessed by USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 N hydrochloric acid; the acceptance criterion is established against the approved oral minoxidil tablet monograph rather than a universal Q value. Tablet compression above the qualified compaction force causes bilayer collapse and leakage of encapsulated minoxidil; therefore, process qualification includes a centrifugation or size-exclusion method to quantify free versus liposomal drug after tablet disintegration. Published data for liposomal minoxidil bilayers under rotary compression is limited, so upper force limits are confirmed batch-to-batch rather than assumed from unrelated liposomal powders. The finished tablets are packaged in opaque HDPE bottles with desiccant because phospholipid hydrolysis accelerates above 25°C and at residual moisture above 2.0% w/w.

The oral route does not require the liposomal bilayer to remain intact after ingestion. Bile salt solubilization and pancreatic phospholipase A2 degrade phosphatidylcholine-based vesicles in the duodenum; the tablet therefore functions as a delivery matrix that alters minoxidil dissolution and possibly early absorption rather than as a stable circulating carrier. This operational boundary must be stated in the pharmaceutical development report and reflected in dissolution specifications.

What Capsule Filling Parameters Maintain Bilayer Integrity in Hard Shell Encapsulation?

Low-dose hard capsules containing 0.25 mg, 0.5 mg, and 1.0 mg liposomal minoxidil are compounded for individualized androgenetic alopecia regimens and clinical trial blinding. The liposomal API powder is mixed with pregelatinized starch and microcrystalline cellulose in a low-shear tumble blender at 15–20 rpm for 10–15 minutes. High-shear granulation is avoided because rotor-tip shear and frictional heating disrupt the lipid bilayer. Filling on a Bosch GKF 700 capsule machine with tamping-pin stations is preferred over dosator settings because dosator compression can locally exceed the yield stress of dried liposomal granules. Tamping pin compression is set to the lowest setting that achieves consistent fill weight; fill-weight RSD is maintained ≤ 2.0% across 10 machine cycles. The filling suite is controlled at 20–25°C and ≤ 40% relative humidity; unencapsulated powder is held in intermediate bulk containers no longer than 4 hours under these conditions. Hard gelatin capsules size 3 or 4 are used, and finished capsules are packaged in HDPE bottles with molecular sieve desiccant and induction-sealed liners. Quality release includes content uniformity by USP <905> with acceptance value ≤ 15, microbial limits by USP <61> and USP <62>, and water determination by USP <921> with limit ≤ 2.5% w/w. Dissolution is evaluated by USP <711> using 0.1 N hydrochloric acid; however, liposomal encapsulation may slow release relative to free minoxidil, and the dissolution profile should be compared to a non-liposomal control batch. Storage below 25°C is required because phospholipid hydrolysis in dried lipid matrices follows Arrhenius behavior and accelerates in humid or hot conditions.

Fluid-bed processing of liposomal minoxidil granules is carried out with a top-spray configuration in a GEA Aeromatic-Fielder MP-1 lab-scale unit. The API is dispersed in a binder solution of povidone K30 at 2–5% w/w in purified water or a water-isopropanol mixture; organic solvent fraction is limited to reduce lipid extraction. Inlet air temperature is set at 50–60°C, and product temperature is held at 28–34°C by adjusting spray rate. Atomizing air pressure is 0.8–1.2 bar. Bed humidity is maintained below 12% RH to avoid phospholipid stickiness and granule agglomeration. Granules are dried to loss-on-drying ≤ 2.0% w/w by USP <731>. Sieve fraction between 180 µm and 710 µm is collected; fines below 125 µm are recycled only once because repeated re-granulation reduces bilayer integrity. The final granule blend is filled into single-dose sachets under ≤ 30% RH.

For reconstituted oral suspension, each sachet is dispersed in purified water to achieve 1.0 mg/mL or 2.5 mg/mL minoxidil. A methylparaben and potassium sorbate preservative system is included only after compatibility study with the liposomal carrier; preservative-induced zeta-potential shifts are a known failure mode. The reconstituted suspension is assigned a beyond-use date of 14 days at 2–8°C in the absence of dedicated stability data. Incompatibility with vehicles containing high ethanol or propylene glycol is noted because these solvents extract phosphatidylcholine from the bilayer and increase free drug fraction. Suspension pH is adjusted to 5.5–6.5; below pH 4.5, minoxidil is fully protonated and lipid hydrolysis increases. Sachet-filled granules are tested for content uniformity by USP <905> and for deliverable volume using USP <698> where applicable.

When Liposomal Minoxidil Is Prepared for Intradermal Administration, Filtration Trains and Tonicity Define the Acceptable Window

Intradermal mesotherapy-grade liposomal minoxidil is prepared by thin-film hydration followed by high-pressure homogenization or sequential extrusion. A bilayer composition of hydrogenated soy phosphatidylcholine, cholesterol, and DSPE-mPEG 2000 at a molar ratio near 56:39:5 is used as a starting point for low-membrane-permeability, stealth-type vesicles; minoxidil-specific optimization of the mole fraction is required because published data for this drug are limited. Passive entrapment of minoxidil in the aqueous core is technically straightforward but yields a low drug-to-phospholipid ratio because minoxidil has high aqueous solubility and a low octanol-water partition coefficient. Remote loading by a transmembrane ammonium sulfate gradient is theoretically possible for this weakly basic compound, pKa approximately 4.6, but the low bilayer permeability of the uncharged species may limit active loading efficiency. If remote loading is used, the internal phase is 250 mM ammonium sulfate, pH 5.0, and the external phase is exchanged by tangential flow filtration to 10 mM histidine with 9% w/v sucrose, pH 6.5. Encapsulation efficiency is measured by size-exclusion chromatography or ultrafiltration with HPLC assay; values above 90% are typical for well-retained weakly basic drugs, but minoxidil-specific data are not publicly established.

The extruded dispersion is passed through stacked polycarbonate membranes 200 nm and 80 nm at a temperature above the lipid phase-transition temperature, typically 60–65°C for HSPC-containing systems. After cooling, the mean particle diameter is controlled at 80–120 nm with polydispersity index ≤ 0.15 by dynamic light scattering; zeta potential is controlled at -20 mV to -35 mV. Sterile filtration through a 0.2 µm polyethersulfone filter is performed aseptically using a low-shear peristaltic pump; terminal autoclaving is not used because lipid hydrolysis and particle aggregation occur at 121°C. The final dispersion is adjusted to 280–320 mOsmol/kg with sodium chloride or dextrose and checked for pH 5.5–6.5. Osmolality is determined by USP <785>. Release tests include sterility per USP <71>, bacterial endotoxins per USP <85>, particulate matter per USP <788>, and visible particulates per USP <790>. The product is stored at 2–8°C; phospholipid hydrolysis and PEG-lipid desorption are known shelf-life failure modes.

Aseptic filling is conducted in an ISO 14644-1 Class 5 environment with unidirectional airflow over the filling needle. The vials are Type I borosilicate glass per USP <660>, and the closures are elastomeric stoppers qualified per USP <381>. Liquid fill weight is controlled to ± 2% of target; overfill is minimized because high lipid concentration increases viscosity. The injection is not intended for intravenous use unless the formulation has completed additional toxicological qualification; the intradermal route uses small volumes of 0.1–0.5 mL per injection site and therefore demands high local dose accuracy.

Lyophilized Cake Design for Reconstituted Parenteral Minoxidil Under Aseptic Conditions

When a dry sterile form is required to reduce hydrolysis, liposomal minoxidil is freeze-dried as a single-dose cake. Sucrose or trehalose is included as a lyoprotectant at a trehalose-to-total-lipid molar ratio of 4:1 to 5:1; lower ratios produce vesicle fusion, and higher ratios reduce cake collapse but increase reconstitution viscosity. The dispersion is filled into 5 mL or 10 mL Type I borosilicate vials with a fill volume of 1.0–2.5 mL and partially stoppered. Freezing is performed at shelf temperature -45°C; an annealing step at -20°C for 2–4 hours is used to facilitate ice crystallization and avoid incomplete solute segregation. Primary drying is carried out at shelf temperature -35°C and chamber pressure 60–120 mTorr; secondary drying is performed at 20–25°C until residual moisture by Karl Fischer is ≤ 1.0% w/w. The cake is stoppered under nitrogen overlay to prevent oxidative degradation of unsaturated lipid fractions. Reconstitution with water for injection should occur in ≤ 60 seconds with gentle swirling; post-reconstitution mean particle diameter should not increase more than 20% compared with the pre-lyophilization value. If drug leakage after reconstitution exceeds 15% of total drug, the lyophilization cycle and lyoprotectant level are considered non-optimized. The reconstituted injection is tested for sterility, bacterial endotoxins, and particulate matter as described for the liquid intradermal form. Published data for lyophilized minoxidil liposome formulations in parenteral use are limited; therefore, cycle parameters must be validated for the exact lipid composition rather than adopted from other liposomal drug products.

Elastomeric closures are selected with low moisture vapor transmission and are qualified per USP <381>. Secondary packaging with aluminum flip-off seals is used, and vials are stored inverted for 24 hours to test container closure integrity by dye ingress according to USP <1207>. Storage is at 2–8°C; freeze-thaw cycling is prohibited because it causes bilayer aggregation and free drug precipitation. The dry cake avoids sterility failure from aseptic filtration of viscous liposomal dispersions, but the reconstitution step introduces a risk of point-of-use contamination; single-dose format is therefore used.

For pediatric oral liquid compounding, the granule intermediate described above is dispersed in a preservative-free or low-preservative aqueous vehicle at a concentration of 1.0 mg/mL. The pH is adjusted with citrate buffer to 5.5, and sucrose is added at 0.2 g/mL as a sweetener and osmotic stabilizer; high-shear mixing is avoided because it breaks liposomal structures. The suspension is used within 7 days at 2–8°C because published stability data for compounded liposomal minoxidil oral liquid are limited. This format is a well-established suspension compounding zone: stability and dosing accuracy control the process, and no additional process optimization is required beyond shaking before dose measurement. Deliverable volume is tested by USP <698>, and dose accuracy is confirmed using graduated oral syringes.